Table 1.
Family | Virus | Species/Variant | Assay | EC50 (μM) [SI] |
||
---|---|---|---|---|---|---|
R1479 | 2′diF-4′N3-C | 2′F-4′N3-C | ||||
Paramyoxviridae | NiV | Rec. M-GFP2AM | REP | 3.1 ± 0.36 [>32] | 0.37 ± 0.11 [>270] | 0.18 ± 0.02 [>555] |
CPE | 2.4 ± 0.22 [>41] | 0.37 ± 0.09 [>270] | 0.23 ± 0.02 [>434] | |||
M-1999 | CPE | 2.9 ± 0.95 [>34] | 0.48 ± 0.19 [>208] | 0.29 ± 0.10 [>344] | ||
VTR | 1.5 [>66]* | 0.36 [>277] | 0.14 [>714] | |||
HeV | 1996 | CPE | 2.1 ± 0.57 [>47] | 0.57 ± 0.11 [>175] | 0.37 ± 0.09 [>270] | |
VTR | 2.4 [>41]* | 0.15 [>666] | 0.15 [>666] | |||
hPIV3 | Rec. JS-GFP | REP | 3.2 ± 0.50 [>32] | 0.44 ± 0.03 [>227] | 0.16 ± 0.02 [>625] | |
MV | Rec. rMVEZGFP(3) | REP | 1.9 ± 0.12 [>52] | 0.34 ± 0.07 [>294] | 0.27 ± 0.04 [>370] | |
Pneumoviridae | RSV | Rec. rgRSV224 (A2) | REP | 3.3 ± 0.39 [>30] | 0.21 ± 0.04 [>476] | 0.28 ± 0.05 [>357] |
Filoviridae | EBOV | Rec. Mayinga-GFP | REP | 2.6 ± 0.85 [>38] | 0.30 ± 0.02 [>333] | 7.79 ± 4.2 [>12] |
Rec. Makona-ZsG | REP | 2.1 ± 0.07 [>47] | 0.33 ± 0.03 [>303] | 3.85 ± 0.09 [>25] | ||
Makona | FFU | 2.1 ± 0.02 [>47] | 0.60 ± 0.08 [>166] | ND [ND] | ||
SUDV | Gulu | FFU | 2.5 [40] | 0.70 ± 0.08 [>142] | 9.57 [>10] | |
VTR | 0.92 [>108] | 0.16 [>625] | 0.30 [>333] | |||
RAVV | Ravn | FFU | 7.4 ± 1.6 [>13] | 0.73 ± 0.16 [>136] | 10.8 ± 4.9 [>9] | |
VTR | 3.0 [>33] | 0.16 [>625] | 6.07 [>16] | |||
Phenuiviridae | RVFV | Rec. ZH501-GFP | REP | >50 [ND] | 44.6 [>2] | >50 [ND] |
EC50, 50% effective inhibition concentration; SI, selective index = EC50/CC50; REP, reporter; CPE, cytopathic effect; VTR, virus titer reduction; FFU, focus-forming unit; ND, not determined; Rec, recombinant; *, data adapted from (Hotard et al., 2017). Mean values with ±standard deviation values were derived from a minimum of 2 independent experiments performed in biological quadruplicate.